RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Oncotarget: Subtypes of thymic epithelial tumors independent of WHO type
(Impact Journals LLC) These Oncotarget results may reflect the unselected patient population enrolled in these studies, including no selection for WHO histologic subtype or molecular aberrations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Epithelial-mesenchymal transitions create endothelial cells and tumor growth
(Impact Journals LLC) Cells that have undergone EMT can promote tumor growth and neovascularization either indirectly, by promoting endothelial transdifferentiation of carcinoma cells, or directly, by acquiring an endothelial phenotype, with FOXC2 playing key roles in these processes (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2021 Category: Cancer & Oncology Source Type: news

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer
FDA granted accelerated approval to capmatinib (TABRECTATM, Novartis) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Yorkie drives Ras-induced tumor progression by microRNA-mediated inhibition of cellular senescence
The activation of Ras signaling is a major early event of oncogenesis in many contexts, yet paradoxically, Ras signaling induces cellular senescence, which prevents tumorigenesis. Thus, Ras-activated cells must overcome senescence to develop into cancer. Through a genetic screen in Drosophila melanogaster, we found that the ETS family transcriptional activator Pointed (Pnt) was necessary and sufficient to trigger cellular senescence upon Ras activation and blocked Ras-induced tumor growth in eye-antennal discs. Through analyses of mosaic discs using various genetic tools, we identified a mechanism of tumor progression in w...
Source: Signal Transduction Knowledge Environment - June 1, 2021 Category: Science Authors: Ito, T., Igaki, T. Tags: STKE Research Articles Source Type: news

MD Anderson Examines Aggressive Mesothelioma Surgery in Latest Study
A retrospective study involving two decades of pleural mesothelioma patients at the heralded University of Texas MD Anderson Cancer Center failed to demonstrate a definitive survival advantage to support regular use of extrapleural pneumonectomy surgery. The most aggressive surgery possible for this type of mesothelioma – once the surgery of choice – showed no clear benefit over a more conservative procedure. When compared to the less-aggressive, lung-sparing pleurectomy and decortication surgery, EPP had a much higher perioperative mortality rate and a shorter median survival. “In comparison, we...
Source: Asbestos and Mesothelioma News - May 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Oncotarget: Inhibition of resistant triple-negative breast cancer cells
(Impact Journals LLC) The Oncotarget author's analyses of protein markers of epithelial-to-mesenchymal transition indicated that treatments with 6-mercaptopurine and/or 5-azacitidine do not significantly reverse this process in their model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

A Look at Three Decades of Real-World Mesothelioma Statistics
Despite clinical trials that often produce inflated expectations, real-world survival rates for pleural mesothelioma have failed to advance significantly over the past three decades, according to one recent study in Canada. Celebrated treatment advances have fallen short for the average patient diagnosed with this rare cancer caused by exposure to asbestos. “This is a story about a lack of progress. What we’ve seen is kind of underwhelming,” Dr. Paul Wheatley-Price, associate professor of medicine at University of Ottawa and thoracic oncologist at The Ottawa Hospital Cancer Centre, told The Mesothel...
Source: Asbestos and Mesothelioma News - May 11, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Molecular analysis identifies key differences in lungs of cystic fibrosis patients
A team of researchers from UCLA, Cedars-Sinai and the Cystic FibrosisFoundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis.The catalog,described today in the journal Nature Medicine, reveals new subtypes of cells and illustrates how the disease changes the cellular makeup of the airways. The findings could help scientists in their search for specific cell types that represent prime targets for genetic and cell therapies for cystic fibrosis.“This new research has provided us with valuable insights into the cellular makeup of both heal...
Source: UCLA Newsroom: Health Sciences - May 7, 2021 Category: Universities & Medical Training Source Type: news

Pleural Mesothelioma Patients with 5-Year Survival Still Rare
Although no amount of asbestos exposure is considered safe, lower levels of non-occupational exposure are most often linked to long-term survival for those diagnosed with malignant pleural mesothelioma, according to a recent study. Clinical Lung Cancer published the study that compared characteristics of 43 pleural mesothelioma patients who survived at least five years with the disease to a much larger control group. Several previous mesothelioma studies have estimated that the five-year survival rate is just under 5% for pleural mesothelioma, an aggressive cancer with no definitive cure. It is caused almost exclusiv...
Source: Asbestos and Mesothelioma News - April 22, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

Some Mesothelioma Patients May Benefit from Second Radical Surgery
This study should elicit a call of hands for centers to share their experiences, to say either do it, or not do it,” Elsayed said. “Right now, you just don’t find a good number of centers doing that second operation.” Earlier Mesothelioma Surgery Studies  This most recent report focused on three smaller studies totaling 40 patients involved in a second major surgery with a curative intent for mesothelioma. In the first group of 16 patients, there was a median survival of 20.4 months after the second surgery for those with epithelial cell type, but only 7.4 months survival for those wit...
Source: Asbestos and Mesothelioma News - March 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New insight into how cancer spreads
(University of Colorado Anschutz Medical Campus) The transformation Ford and her team are studying happens when cells called epithelial cells, which are more adherent to one another and less likely to spread to other parts of the body, start to take on the characteristics of mesenchymal cells, which are more migratory and more likely to invade other parts of the body. This transformation is referred to as the epithelial-to-mesenchymal transition. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

Discovery of a mechanism by which epithelial tumours cause developmental delays
(Institute for Research in Biomedicine (IRB Barcelona)) - Conducted on the fly Drosophila, the study shows that tumours caused by chromosomal instability delay entry into the adult phase.- The tumours produce the Upd3 protein (equivalent to human Interleukin-6) to block the production of developmental steroid hormones.- The work of IRB Barcelona's Growth Control and Development laboratory has been published in the journal Current Biology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2021 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Review supports surgical excision for FEA breast lesions
There's enough evidence to support surgical excision of flat epithelial atypia...Read more on AuntMinnie.comRelated Reading: Can MRI-guided breast biopsy evaluate chemo response? Can AI spot breast cancer years before radiologists? Food, housing insecurity tied to breast biopsy delay Image-guided biopsy spots residual breast cancer Surveillance OK for certain type of breast lesion (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 25, 2021 Category: Radiology Source Type: news

Study: Mesothelioma Survival Rates Rise with SMART Protocol
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a larger clinical trial at the Princess Margaret Cancer Centre in Toronto. Lancet Oncology recently published results of the study, named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. The SMART study involved 96 patients with pleural mesothelioma who were treated in Toronto from 2008 to 2019. All received the intensity-modulated radiotherapy before extrapleural pneumonectomy surgery, an unconventional treatment regimen. Among the...
Source: Asbestos and Mesothelioma News - January 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer ASCO Advises Against PARP Inhibitor Retreatment in Ovarian Cancer
New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC).Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 29, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Thymoquinone induces apoptosis & DNA damage in 5-Fluorouracil-resistant colorectal cancer
(Impact Journals LLC) Volume 11, Issue 31 from @Oncotarget reported that TQ decreased the expression levels of colorectal stem cell markers CD44 and Epithelial Cell Adhesion Molecule Ep CAM and proliferation marker Ki67 in colonospheres derived from both cell lines and reduced cellular migration and invasion. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2020 Category: Cancer & Oncology Source Type: news

Oncotarget: Induction of phenotypic changes in HER2-postive breast cancer cells
(Impact Journals LLC) The cover for issue 30 of Oncotarget features Figure 4, " RNAseq results demonstrating differences between normal, cancer, and redirected cells, " by Frank-Kamenetskii, et al. which reported that the influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2020 Category: Cancer & Oncology Source Type: news

Trends in treatment, survival among women with advanced ovarian cancer
(JAMA Network) This observational study examined survival rates and the use of chemotherapy before surgery among women with advanced-stage epithelial ovarian cancer in the United States from 2004 to 2016. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 25, 2020 Category: International Medicine & Public Health Source Type: news

How airway cells work together in regeneration and aging
Researchers at theEli and Edythe Broad Center of  Regenerative Medicine and Stem Cell Research at UCLA have identified the process by which stem cells in the airways of the lungs switch between two distinct phases — creating more of themselves and producing mature airway cells — to regenerate lung tissue after an injury.The study, published in Cell Stem Cell, also sheds light on how aging can cause lung regeneration to go awry, which can lead to lung cancer and other diseases.  “There currently are few therapies that target the biology of lung diseases,” said Dr. Brigitte Gomperts,a profes...
Source: UCLA Newsroom: Health Sciences - July 27, 2020 Category: Universities & Medical Training Source Type: news

More Mesothelioma Cancer Centers Using Tumor Treating Fields
Tumor Treating Fields is one of the newest treatments on the market for pleural mesothelioma cancer patients with metastatic disease. The device is also available to patients with locally advanced cancer who are not candidates for mesothelioma surgery. Clinical trials of the treatment, previously known as NovoTTF-100L, extended the survival of mesothelioma patients by more than six months compared to those receiving only chemotherapy. The device is now called Optune Lua and has been available outside of clinical trials for over a year. More physicians and treatment centers are becoming certified to prescribe the treatmen...
Source: Asbestos and Mesothelioma News - July 21, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

NCI Studying New Mesothelioma Immunotherapy Combination
Patients with mesothelioma are being recruited by the National Cancer Institute for a phase II clinical trial using a novel immunotoxin prior to pembrolizumab, a combination that has shown preliminary evidence of efficacy. This promising mesothelioma clinical trial involves the drug LMB-100, designed to make immunotherapy agents such as pembrolizumab, otherwise known as Keytruda, more effective. NCI’s trial includes separate cohorts for pleural and peritoneal types of mesothelioma. “This is a very good option for these patients,” medical oncologist Dr. Raffit Hassan, an acclaimed investigator at the Natio...
Source: Asbestos and Mesothelioma News - July 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Oncotarget: Epigenetic feedback and stochastic partitioning can drive resistance to EMT
(Impact Journals LLC) Oncotarget Volume 11, Issue 27 published " Epigenetic feedback and stochastic partitioning during cell division can drive resistance to EMT " by Jia et al. which reported that Epithelial-mesenchymal transition (EMT) and its reverse process mesenchymal-epithelial transition are central to metastatic aggressiveness and therapy resistance in solid tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Moffitt researchers identify protein that causes epithelial cancers to spread
(H. Lee Moffitt Cancer Center& Research Institute) In a new article published in the July issue of Cancer Research, Elsa Flores, Ph.D., and her team discovered a key protein that oscillates its expression through microRNA regulation to facilitate cancer spread to distant organs. This protein is deltaNp63, a member of the p53 family of tumor suppressor genes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2020 Category: International Medicine & Public Health Source Type: news

Hidden Cause of Cancer?
When you’re tearing off a sheet of aluminum foil to cook with — or wrap your leftovers before you put them in the fridge — you probably never consider aluminum is a dangerous toxin. Truth is, aluminum is a heavy metal… just like lead, mercury and arsenic. It’s in our food… our cookware… even in the water we drink. Exposure to aluminum is a risk factor for cancer, Alzheimer’s, Parkinson’s, and bone disease, just to name a few. Our lungs, liver, and kidneys are able to eliminate a majority of the small amounts of aluminum we ingest through eating, drinking or breath...
Source: Al Sears, MD Natural Remedies - May 29, 2020 Category: Complementary Medicine Authors: Dr.A.Sears Tags: Health Source Type: news

Cervical precancer identified by fluorescence, in a step toward bedside detection
(Tufts University) Researchers developed a method using fluorescence to detect precancerous metabolic and physical changes in individual epithelial cells lining the cervix, and can visualize those changes at different depths of the epithelial tissue near the surface. The method, which can detect precancerous lesions non-invasively and non-destructively, opens the door to early-stage bedside diagnostics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Olaparib/Bevacizumab Maintenance FDA Approves Olaparib/Bevacizumab Maintenance
The FDA has announced a new approved indication for olaparib in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab
The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Epithelial GPS: Position of RNAi machinery is associated with epithelial identity
(Medical University of South Carolina) Researchers at the Medical University of South Carolina show in a new report that the RNA interference machinery, normally thought to reside in the nucleus or cytoplasm, predominantly localizes to these apical junctions and influences cell biology in the colon. Interestingly, in colon tumors, this localization is dysregulated and may shift the balance of RNAs to promote tumorigenesis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Niraparib for Advanced Ovarian Cancer
The FDA approved niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Ovarian cancer: recognition and initial management [CG122], NICE (Published 27th April)
This guideline covers detecting, diagnosing and treating women (18 years and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment. This guideline was previously called ovarian cancer: the recognition and initial management of ovarian cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 27, 2020 Category: Consumer Health News Source Type: news

Analysis of Stage I EFHWTs Treatment Finds Event-Free Survival and Overall Survival Rates Greater Than 95%
A recent study reported a 96.2% event-free survival rate and a 100% overall survival rate when investigating treatment option for stage I epithelial-predominant favorable-histology Wilms tumors in a population with a majority of patients under the age of 48 months. (Source: CancerNetwork)
Source: CancerNetwork - April 23, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies
Breast and mammary epithelial cells experience different local environments during tissue development and tumorigenesis. Microenvironmental heterogeneity gives rise to distinct cell regulatory states whose identity and importance are just beginning to be appreciated. Cellular states diversify when clonal three-dimensional (3D) spheroids are cultured in basement membrane, and one such state is associated with stress tolerance and poor response to anticancer therapeutics. Here, we found that this state was jointly coordinated by the NRF2 and p53 pathways, which were costabilized by spontaneous oxidative stress within 3D cult...
Source: Signal Transduction Knowledge Environment - April 13, 2020 Category: Science Authors: Pereira, E. J., Burns, J. S., Lee, C. Y., Marohl, T., Calderon, D., Wang, L., Atkins, K. A., Wang, C.-C., Janes, K. A. Tags: STKE Research Articles Source Type: news

Extracellular forces help epithelial cells stick together
(University of Helsinki) Defects in the maintenance of the superficial tissue of the body, known as epithelial tissue, can help cancer cells achieve motility and metastasize. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2020 Category: Cancer & Oncology Source Type: news

Ex ­ tra ­ cel ­ lu ­ lar forces help epi ­ thelial cells stick to ­ gether
(University of Helsinki) Defects in the maintenance of the superficial tissue of the body, known as epithelial tissue, can help cancer cells achieve motility and metastasise. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 2, 2020 Category: International Medicine & Public Health Source Type: news

Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis
Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors, but only a small subset of these cells generates metastases. We conducted an in vivo genome-wide CRISPR activation screen in CTCs from breast cancer patients to identify genes that promote distant metastasis in mice. Genes coding for ribosomal proteins and regulators of translation were enriched in this screen. Overexpression of RPL15, which encodes a component of the large ribosomal subunit, increased metastatic growth in multiple organs and selectively enhanced translation of other ribosomal proteins and cell cycle regulators. RNA sequencin...
Source: ScienceNOW - March 25, 2020 Category: Science Authors: Ebright, R. Y., Lee, S., Wittner, B. S., Niederhoffer, K. L., Nicholson, B. T., Bardia, A., Truesdell, S., Wiley, D. F., Wesley, B., Li, S., Mai, A., Aceto, N., Vincent-Jordan, N., Szabolcs, A., Chirn, B., Kreuzer, J., Comaills, V., Kalinich, M., Haas, W. Tags: Medicine, Diseases, Molecular Biology reports Source Type: news

Learning how cancer cells coordinate and collaborate to multiply and metastasize
(Osaka University) Researchers from Osaka University and the National Institute of Information and Communications Technology have cultured epithelial-like cancer cells on an artificial substrate and observed their collaborative self-organization into network structures that may function as nutritional conduits and provide vascular access. Understanding of the parameters that govern this coordinated behavior, including the various forces responsible, may explain tumor growth and metastasis, thus providing a basis for developing new anticancer drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2020 Category: Cancer & Oncology Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1...
Source: Johnson and Johnson - March 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript
FDA medical oncologists discuss the agency ’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

MicroRNA regulates process vital to placenta growth in early pregnancy
(University of South Florida (USF Health)) A study by University of South Florida Health (USF Health) researchers discovered how a very large human non-protein coding gene regulates epithelial-to-mesenchymal transition (EMT) -- a process that contributes to placental implantation during early pregnancy, as well as cancer progression and spread. EMT plays a key role in proper placenta growth, critical to the health of the mother and her growing fetus. The USF Health team showed that robustly activating the chromosome 19 microRNA cluster using CRISPR technology inhibited EMT. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 25, 2020 Category: International Medicine & Public Health Source Type: news

Duke Completes Largest Study of Mesothelioma in Women
This study of women included 275 cases of pleural mesothelioma and 79 cases of peritoneal. Papillary mesothelioma and localized mesothelioma cases were excluded. Previous reports have shown that 22% to 29% of mesothelioma cases involve women, but only 12% in this particular study. Other Notable Takeaways The majority of those studied were exposed to asbestos through household contact. Women who worked in occupations and industries associated with higher asbestos exposure had objective markers of exposure similar to men. Survival was longer for the epithelial subtype of mesothelioma and magnified with the per...
Source: Asbestos and Mesothelioma News - February 5, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease
(Impact Journals LLC) The authors determined that tumor-derived ANGPTL2 stimulates lung epithelial cells, which is essential for primary tumor-induced neutrophil recruitment in lung and subsequent pre-metastatic niche formation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news